YCAAP (Yaksh C Alzheimer’s Affected Plan) A Conceptual, Quality-of-Life–Oriented Framework for Early Alzheimer’s Disease.

-Author InformationAuthor: Yaksh ChudasamaAge: 17 years, Class 12 student Affiliation: Independent Student Researcher Email: yaksh.science@gmail.comI am a 17-year-old Class 12 student exploring medical sciences and theoretical biology. This work represents my early thinking on Alzheimer’s disease and patient-centered frameworks. I have no clinical training, and this is purely conceptual. I welcome constructive feedback, critique, and discussion from researchers, clinicians, and peers.AbstractAlzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β accumulation, tau pathology, synaptic dysfunction, neuroinflammation, and gradual cognitive decline. Despite extensive research, definitive curative therapies remain elusive.The YCAAP (Yaksh C Alzheimer’s Affected Plan) proposes a damage-control, quality-of-life–oriented conceptual framework for early-stage Alzheimer’s disease. Instead of attempting to cure the disease, YCAAP emphasizes temporary functional stabilization using: Environmental modulation Cautious biochemical biasing Intermittent neurotransmitter support Supportive care integration This framework is theoretical, non-interventional, and intended to inspire discussion, refinement, and ethical exploration.1. Background and RationaleAlzheimer’s disease progressively alters the brain’s environment, making it biologically hostile through protein misfolding, oxidative stress, immune dysregulation, and synaptic dysfunction. Early in the disease, however, many neurons remain alive but functionally compromised.YCAAP reframes the therapeutic goal: rather than seeking an unattainable cure at this stage, it focuses on preserving function and quality of life, improving daily experience for patients and easing caregiver burden. Even temporary improvements can have profound human value.2. Pathological Considerations2.1 Amyloid-β ToxicityAmyloid-β oligomers disrupt neurons through aggregation, synaptic interference, metal-ion binding, and oxidative stress. Complete elimination has shown limited benefit once downstream pathology is established.YCAAP perspective: Reduce functional toxicity instead of attempting full elimination, by modifying the biochemical context subtly.2.2 Metal-Ion–Associated NeurotoxicityMetal ions (Cu²⁺, Zn²⁺, Fe³⁺) stabilize amyloid aggregates and promote oxidative stress.YCAAP perspective: Low-intensity, targeted modulation may reduce oxidative toxicity while preserving normal neuronal metal balance.2.3 Neurotransmission DeclineCholinergic deficits drive early cognitive decline in AD.YCAAP perspective: Intermittent support of acetylcholine signaling may temporarily improve cognition and attention without continuous overstimulation.3. Conceptual Framework Components Environmental and Metabolic Modulation Reduce oxidative stress and cellular stressors Avoid aggressive metabolic interventions that could worsen tau hyperphosphorylation Neurotransmitter Support Intermittent, cautious enhancement of cholinergic activity Focused on short-term functional stabilization Supportive and Palliative Integration Nutritional optimization Environmental and routine stability Cognitive and emotional support 4. Hypothetical Outcomes Short-term (weeks to months): Improved attention, partial restoration of daily function, reduced caregiver burden, maintained communication and identity Medium-term: Benefits plateau; gradual cognitive decline continues due to ongoing pathology Long-term: No disease reversal; framework transitions to fully palliative support 5. Limitations and Ethical Boundaries This framework does not claim to cure or modify disease Benefits are temporary and patient-specific Conceptual only; no clinical recommendations Requires careful consideration to avoid unintended harm 6. Positioning and PurposeYCAAP aligns with: Palliative neurology principles Patient-centered care Ethical exploration of supportive interventions It is intended as a discussion starter, a conceptual “bridge” between early-stage patient care and ongoing research, rather than a therapeutic protocol.7. Invitation for CritiqueAs a 17-year-old independent researcher, I welcome constructive feedback, suggestions, and discussion from medical professionals, neuroscientists, and fellow students. My goal is to refine this concept responsibly and learn from experienced voices.8. Attribution and UseThis document is shared for academic discussion only. Please retain attribution and context if sharing. Commercial use or uncredited reproduction is discouraged. (note - This work is licensed under CC BY-NC-ND 4.0. Attribution is required. No commercial use or derivative works are allowed )9. DisclaimerThis work is educational and conceptual only. It does not constitute medical advice, a clinical protocol, or a validated treatment. No clinical application is implied.THANK YOU!*Version 1.0 – Initial conceptual framework (15th January 2026)*